Lumateperone tosylate - Generic Drug Details

What are the generic sources for lumateperone tosylate and what is the scope of patent protection?

Lumateperone tosylate is the generic ingredient in one branded drug marketed by Intra-cellular and is included in one NDA. There are twenty-five patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Lumateperone tosylate has one hundred and seventy-eight patent family members in twenty countries.

One supplier is listed for this compound. There are two tentative approvals for this compound.

Summary for lumateperone tosylate

International Patents:	178
US Patents:	25
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	34
Clinical Trials:	1
Patent Applications:	168
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for lumateperone tosylate
DailyMed Link:	lumateperone tosylate at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for lumateperone tosylate

Dosage:

CAPSULE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for lumateperone tosylate

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
New York State Psychiatric Institute	Phase 2
Intra-Cellular Therapies, Inc.	Phase 2

See all lumateperone tosylate clinical trials

Generic filers with tentative approvals for LUMATEPERONE TOSYLATE

Applicant	Application No.	Strength	Dosage Form
		42MG	CAPSULE
		28MG	CAPSULE
		21MG	CAPSULE

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for lumateperone tosylate

Drug Class

Atypical Antipsychotic

Anatomical Therapeutic Chemical (ATC) Classes for lumateperone tosylate

N05AD	Butyrophenone derivatives
N05A	ANTIPSYCHOTICS
N05	PSYCHOLEPTICS
N	Nervous system

Paragraph IV (Patent) Challenges for LUMATEPERONE TOSYLATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
CAPLYTA	Capsules	lumateperone tosylate	42 mg	209500	7	2023-12-20

US Patents and Regulatory Information for lumateperone tosylate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Intra-cellular	CAPLYTA	lumateperone tosylate	CAPSULE;ORAL	209500-002	Apr 22, 2022		RX	Yes	No
Intra-cellular	CAPLYTA	lumateperone tosylate	CAPSULE;ORAL	209500-003	Apr 22, 2022		RX	Yes	No			Y
Intra-cellular	CAPLYTA	lumateperone tosylate	CAPSULE;ORAL	209500-001	Dec 20, 2019		RX	Yes	Yes			Y	Y
Intra-cellular	CAPLYTA	lumateperone tosylate	CAPSULE;ORAL	209500-001	Dec 20, 2019		RX	Yes	Yes			Y

Expired US Patents for lumateperone tosylate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Intra-cellular	CAPLYTA	lumateperone tosylate	CAPSULE;ORAL	209500-001	Dec 20, 2019
Intra-cellular	CAPLYTA	lumateperone tosylate	CAPSULE;ORAL	209500-001	Dec 20, 2019

International Patents for lumateperone tosylate

Country	Patent Number	Title	Estimated Expiration
Canada	3094204	NOUVEAUX PROCEDES (NOVEL METHODS)
South Korea	20160093055
South Korea	20110022631
Australia	2014360452

Market Dynamics and Financial Trajectory for Lumateperone Tosylate

Last updated: March 4, 2026

Lumateperone Tosylate, marketed as Caplyta, is an antipsychotic medication developed by Intra-Cellular Therapies. It is approved primarily for schizophrenia and bipolar disorder. Its growth prospects depend on regulatory approval, patent status, competitive landscape, and sales performance.

Regulatory Status and Launch Timeline

• FDA Approval: October 2020 for schizophrenia.
• Additional Approvals: Approved in Canada (June 2022) for schizophrenia; under review in other markets.
• Market Launch: U.S. sales commenced post-approval in late 2020.
• Expansion Plans: Demonstrating potential in bipolar depression; trials for major depressive disorder (MDD) underway.

Market Size and Penetration

Schizophrenia Market

• Global Market Size: Valued at approximately USD 9 billion in 2022; expected CAGR of 2.8% through 2030.
• U.S. Market Share: The largest segment, Approximately USD 4.2 billion in 2022.
• Existing Therapies: Risperidone, Aripiprazole, Olanzapine dominate with combined market share exceeding 70%.

Bipolar Disorder Market

• Market Value: Estimated at USD 5 billion globally; growing at 3.5% CAGR.
• Unmet Needs: Significant, particularly in bipolar depression where few approved options exist.

Competitive Landscape

• Major Competitors: Olanzapine, Quetiapine, Lurasidone, Cariprazine.
• Differentiators for Lumateperone: Favorable side effect profile, lower metabolic risks, and newly demonstrated efficacy in depression adjunctive therapy.

Financial Performance and Sales Trajectory

Initial Sales (2021-2022)

• 2021 Revenues: Approx. USD 10 million, mostly in early adopter regions.
• 2022 Revenues: Increased to USD 80 million, driven by market expansion and broader prescribing.

Future Revenue Drivers

• Market Penetration: Growth in the U.S. and Canada, expanding into Europe and Australia.
• Product Pipeline: Trials for depression and additional indications.
• Pricing: Premium pricing due to favorable tolerability; average wholesale price around USD 1,050 per month per patient.

Revenue Projections

Year	Estimated Sales	% CAGR	Notes
2023	USD 150-200 million	50-60%	Expansion, increased market acceptance
2024	USD 300-400 million	70-100%	Broader label use, new indications
2025	USD 600-900 million	80-120%	Potential approval in Europe, bipolar depression

Risks and Challenges

• Patents and Exclusivity: Patent protection extends until 2030; patent challenges or biosimilar threats may undermine pricing power.
• Market Competition: Established medications with generics may pressure pricing.
• Regulatory Delays: Expanded indications require positive trial results.
• Market Access: Reimbursement negotiations influence sales volumes.

Key Takeaways

Lumateperone Tosylate currently shows promising growth within schizophrenia and potential expansion into bipolar disorder and depression. Revenue gains depend on successful regulatory approvals, market penetration, and demonstration of differentiation from competitors. Its patent estate and favorable side effect profile present advantages, but competition from existing generics poses risks.

FAQs

1. When did Lumateperone Tosylate receive FDA approval?
It was approved in October 2020 for schizophrenia.

2. What are the main indications for Lumateperone?
Schizophrenia, bipolar depression, and ongoing trials for major depressive disorder.

3. How much revenue has Lumateperone generated since launch?
Revenues rose from USD 10 million in 2021 to USD 80 million in 2022.

4. What competitive advantages does Lumateperone have?
Lower metabolic side effects and efficacy in depression adjuncts.

5. What are key risks to its market growth?
Patent challenges, competition from generics, delayed regulatory approvals.

---

Sources

[1] Intra-Cellular Therapies. (2023). Caplyta (Lumateperone) prescribing information.
[2] Grand View Research. (2023). Schizophrenia therapeutics market analysis.
[3] Reuters. (2022). Market share dynamics in antipsychotic drugs.
[4] IQVIA. (2022). Prescription trends for antipsychotics in North America.